Abbvie Q1 2025. Adjusted diluted eps of $11.11, a decrease of 19.3 percent; View all earnings call transcripts.
No use of any abbvie. Abbvie on friday beat wall street expectations in its first quarter of 2025, thanks in part to robust sales of its immunology drugs rinvoq and skyrizi, the company.
April 26, 2025 At 7:44 A.m.
Abbvie (nyse:abbv) has updated its earnings outlook for the first quarter of 2025 to reflect a dilutive impact related to its acquisition of cancer drugmaker immunogen.
Abbv) Q1 2025 Earnings Call Transcript April 26, 2025.
Abbvie inc (abbv) q1 2025 earnings:
Comprehensive Analysis Of Abbvie's Latest Financial.
Images References :
Abbv) Q1 2025 Earnings Call Transcript April 26, 2025.
Welcome to the abbvie first quarter 2025 earnings conference call.
Adjusted Eps Tops Estimates Despite Revenue Challenges.
[operator instructions] today’s call is also being recorded.